European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 96, Issue 2 , Pages 187-192 , June 2001

Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study

Received 23 February 2000 ,Revised 6 June 2000 ,Accepted 4 July 2000.

References 

  1. Navot D, Berg PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil. Steril. 1992;58:249–261
  2. Borenstein R, Elhalah U, Lunenfeld B, Schwarts ZS. Severe ovarian hyperstimulation syndrome. Fertil. Steril. 1989;51:791–795
  3. Mathur RS, Joles LA, Akande AV, Jenkins JM. The prevention of ovarian hyperstimulation syndrome. Br. J. Obstet. Gynaecol. 1996;103:740–746
  4. Asch RH, Li HP, Balmeceda JP, Weekstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted repoductive technology: definition of high risk groups. Hum. Reprod. 1991;6:1395–1399
  5. Balasch J, Arroyo V, Carmona F. Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertil. Steril. 1990;56:1077–1083
  6. Navot D, Margalioth EH, Laufer N. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil. Steril. 1987;28:141–143
  7. Mc Clure N, Healy DL, Paw R. Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome. 1994;344:235–243
  8. Asch RH, Ivery G, Goldman M. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum. Reprod. 1993;8:1015–1020
  9. Shoham Z, Weismann A, Barash A. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective randomised, placebo-controlled study. Fertil. Steril. 1994;62:137–142
  10. Shalev E, Giladi Y, Matilsky M, Ben-Ami M. Decreased incidence of severe ovarian hyperstimulation syndrome in high-risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum. Reprod. 1995;10:1373–1376
  11. Isik AZ, Gökmen O, Zeyneloðlu HB, Kara S, Keles G, Gulekli B. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective randomized and controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 1996;70:179–183
  12. Ring J, Messmer K. Incidence and severity of anaphylactic reactions to colloid volume substitutes. Lancet. 1977;1:466–469
  13. Graf MA, Fischer R, Naether OGJ, Baukloh V, Tafel J, Nückel M. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Hum. Reprod. 1997;12:2599–2602
  14. König E, Bussen S, Süterlin M, Steck T. Prophylactic intravenous hydroxyethyl starch solution prevents moderate–severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective randomised double-blind and placebo controlled study. Hum. Reprod. 1998;13:2421–2424
  15. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil. Steril. 1978;30:255–268
  16. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum estradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum. Reprod. 1995;10:811–814
  17. Mukherjee T, Copperman AB, Sandler B. Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in-vitro fertilisation and embryo transfer. Fertil. Steril. 1995;64:641–643
  18. Orvieto R, Dekel A, Dicker D. A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertil. Steril. 1995;64:860–862
  19. Halme J, Toma SK, Talbert LM. A case of severe ovarian hyperstimulation syndrome in a healthy oocyte donor. Fertil. Steril. 1995;64:857–859
  20. Lewit N, Kol S, Ronen N, Itskovitz-Eldor J. Does intravenous administration of human albumin perevent severe ovarian hyperstimulation syndrome?. Fertil. Steril. 1996;66:654–656
  21. Moutus DM, Miller MM, Mahadevan MM. Bilateral internal jugular venous thromsosis complicating severe ovarian hyperstimulation syndrome after prophylactic albumin administration. Fertil. Steril. 1997;68:174–176
  22. Chen CD, Wu MY, Yang JH. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil. Steril. 1997;68:287–291
  23. Shatney CH, Krishnapradad D, Militello PR. Efficacy of hetastarch in the resuscitation of patients with multisystem trauma and shock. Arch. Surg. 1983;118:804–809
  24. Warren B, Durieux ME. Hydroxyethyl starch: safe or not?. Anesth. Analg. 1997;84:206–212
  25. Mac Intyre E, Mackie IJ, Ho D. The hemostatic effects of hydroxyethyl starch used as a volume expander. Intensive Care Med. 1985;11:300–303
  26. Rackow EC, Mecher C, Astiz ME. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit. Care Med. 1989;17:394–398
  27. Boldt, Heesen M, Muller M, Pabsdorf M, Hempelmann G. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. Anesth Analg 1996;83:254–61.
  28. Vogt N, Bothner U, Georgieff M. Comparison of 5% human albumin and 6% 200/0.5 HES as exclusive colloid components in large surgical interventions. Anestesiol. Intensivmed Notfallmed Schmertzer. 1994;29:150–156
  29. Diehl JT, Lester JL, Cosprove DM. Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Ann. Thorac. Surg. 1982;34:674–679
  30. Altman C, Bernard M, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur. J. Gastroenterol. Hepatol. 1998;10:5–10
  31. Kohler H, Kirch W, Horstmann HJ. Hydroxyethyl starch induced macroamylasemia. Int. J. Clin. Pharmacol. 1977;15:428–431
  32. Jurecka W, Szepfalusi Parth E, Schimetta W. Hydroxyethyl starch deposits in human skin — a model for puriritus. Arch. Dermatol. Res. 1993;285:13–19
  33. Kupiotis S, Quehenberger P, Eichter H. Effects of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: comparison with albumin. Crit. Care Med. 1994;22:606–612
  34. Saygili E, Ugur M, Tonguc E, Gungor M, Kirazci S, Ekin M, Gokmen O. Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state? In: Proceedings of the 11th World Congress on In vitro Fertilization and Human Reproductive Genetics, 1999; Sydney, Australia. Abstract Book
  35. Klotz U, Kroemer H. Clinical pharmacokinetic considerations the use of plasma expanders. Clin. Pharmacokinet. 1987;12:123–135

☆ Presented at the 11th World Congress on In vitro Fertilization and Human Reproductive Genetics, 9–14 May 1999, Sydney, Australia.

PII: S0301-2115(00)00452-8

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 96, Issue 2 , Pages 187-192 , June 2001

Article Tools